Vifor Pharma Stock Forecast, Price & News

0.00 (0.00 %)
(As of 08/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume546 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GNHAY News and Ratings via Email

Sign-up to receive the latest news and ratings for Vifor Pharma and its competitors with MarketBeat's FREE daily newsletter.

Vifor Pharma logo

About Vifor Pharma

Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The firm offers products for iron deficiency, nephrology, and cardio-renal therapies. The company was founded in 1927 and is headquartered in St. Gallen, Switzerland.


Vifor Pharma (OTCMKTS:GNHAY) Trading 9.7% Higher
Vifor Pharma (OTCMKTS:GNHAY) Trading 9.7% Higher
July 22, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.45 out of 5 stars

Medical Sector

1900th out of 2,226 stocks

Drug Manufacturers—Specialty & Generic Industry

52nd out of 88 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Vifor Pharma (OTCMKTS:GNHAY) Frequently Asked Questions

Is Vifor Pharma a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vifor Pharma in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Vifor Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GNHAY, but not buy additional shares or sell existing shares.
View analyst ratings for Vifor Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Vifor Pharma?

Wall Street analysts have given Vifor Pharma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vifor Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Vifor Pharma's key executives?

Vifor Pharma's management team includes the following people:
  • Stefan Schulze, President, Chief Executive & Operating Officer
  • Colin Bond, Chief Financial Officer
  • Klaus Henning Jensen, Chief Medical Officer
  • Gregory Oakes, Executive Vice President & President-North America
  • Michael Puri, Chief Human Resources Officer & Senior VP

Who are some of Vifor Pharma's key competitors?

What is Vifor Pharma's stock symbol?

Vifor Pharma trades on the OTCMKTS under the ticker symbol "GNHAY."

How do I buy shares of Vifor Pharma?

Shares of GNHAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vifor Pharma's stock price today?

One share of GNHAY stock can currently be purchased for approximately $28.36.

How many employees does Vifor Pharma have?

Vifor Pharma employs 147,000 workers across the globe.

What is Vifor Pharma's official website?

The official website for Vifor Pharma is www.viforpharma.com.

How can I contact Vifor Pharma?

The company can be reached via phone at (158) 851-8000.

This page was last updated on 8/3/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.